These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19563245)

  • 1. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.
    Vlak T; Kaštelan D; Lozo P; Aljinović J; Gradišer M; Mijić S; Nikolić T; Miškić B; Car D; Tajšić G; Dušek T; Jajić Z; Grubišić F; Poljičanin T; Bakula M; Džubur F; Strižak-Ujević M; Kadojić M; Radman M; Vugrinec M; Kuster Z; Pekez M; Radović E; Labar L; Crnčević-Orlić Z; Koršić M
    Clin Rheumatol; 2011 Dec; 30(12):1549-54. PubMed ID: 21956235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
    Emkey R; Koltun W; Beusterien K; Seidman L; Kivitz A; Devas V; Masanauskaite D
    Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study.
    Oh KW; Kim DY; Lee YS; Kang MI;
    J Bone Miner Metab; 2012 May; 30(3):359-66. PubMed ID: 22083905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women.
    Flood EM; Beusterien KM; Green H; Shikiar R; Baran RW; Amonkar MM; Cella D
    Health Qual Life Outcomes; 2006 Jul; 4():42. PubMed ID: 16834773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
    García-Hernández P; Carranza-Lira S; Motta-Martínez E
    Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
    Kastelan D; Lozo P; Stamenkovic D; Miskic B; Vlak T; Kolak Z; Milas Ahic J; Altabas V; Crncevic Orlic Z; Korsic M
    Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.
    Kastelan D; Vlak T; Lozo P; Gradiser M; Mijic S; Nikolic T; Miskic B; Car D; Tajsic G; Dusek T; Jajic Z; Grubisic F; Poljicanin T; Bakula M; Dzubur F; Strizak-Ujevic M; Kadojic M; Radman M; Vugrinec M; Kuster Z; Pekez M; Radovic E; Labar L; Crncevic-Orlic Z; Korsic M
    Endocr Res; 2010; 35(4):165-73. PubMed ID: 20868288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-monthly dosing: an effective step forward.
    Reid DM
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
    Hadji P; Minne H; Pfeifer M; Bourgeois P; Fardellone P; Licata A; Devas V; Masanauskaite D; Barrett-Connor E
    Joint Bone Spine; 2008 May; 75(3):303-10. PubMed ID: 18069036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.
    Derman R; Kohles JD; Babbitt A
    Clin Interv Aging; 2009; 4():357-65. PubMed ID: 19851511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD; Epstein S; Sedarati F; Reginster JY
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.